Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England

被引：76
作者：
Amin-Chowdhury, Zahin [1 ]
Aiano, Felicity [1 ]
Mensah, Anna [1 ]
Sheppard, Carmen L. [2 ]
Litt, David [2 ]
Fry, Norman K. [1 ,2 ]
Andrews, Nick [3 ]
Ramsay, Mary E. [1 ,4 ]
Ladhani, Shamez N. [1 ,5 ]
机构：
[1] Publ Hlth England, Immunisat & Countermeasures Div, 61 Colindale Ave, London NW9 5EQ, England
[2] Publ Hlth England, Resp & Vaccine Preventable Bacterial Reference Un, London, England
[3] Publ Hlth England, Stat Modelling & Econ Dept, London, England
[4] London Sch Hyg & Trop Med, London, England
[5] St Georges Univ London, Paediat Infect Dis Res Grp PIDRG, London, England
来源：
CLINICAL INFECTIOUS DISEASES | 2021年 / 72卷 / 05期
关键词：
pneumococcal disease; bacterial coinfection; nosocomial infection; case fatality; risk factor; INFLUENZA; VACCINE; WALES; SEROTYPES; INCREASE;
D O I：
10.1093/cid/ciaa1728
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background. Streptococcus pneumoniae coinfection with influenza results in synergistic lethality, but there are limited data on pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods. Public Health England conducts invasive pneumococcal disease (IPD) and SARS-CoV-2 surveillance in England. IPD trends during 2000/2001-2019/2020 epidemiological years were analyzed and cases during February-June 2020 linked with laboratory-confirmed SARS-CoV-2 infections. Multivariable logistic regression was used to assess risk factors for death. Results. IPD incidence in 2019/2020 (7.6/100 000; n = 3964) was 30% (IRR, .70; 95% CI, .18-2.67) lower compared with 2018/2019 (10.9/100 000; n = 5666), with large reductions observed across all age groups during March-June 2020. There were 160 886 SARS-CoV-2 and 1137 IPD cases during February-June 2020, including 40 IPD/coronavirus disease 2019 (COVID-19) co-infections (.025% [95% CI, .018-.034] of SARS-CoV-2 infections; 3.5% [2.5-4.8] of IPD cases), 21 with COVID-19 diagnosed 3-27 days after IPD, and 27 who developed COVID-19 >28 days after IPD. Case-fatality rates (CFRs) were 62.5 (25/40), 47.6% (10/21), and 33.3% (9/27), respectively (P < .001). In addition to an independent association with increasing age and serotype group, CFR was 7.8-fold (95% CI, 3.8-15.8) higher in those with IPD/COVID-19 coinfection and 3.9-fold (95% CI, 1.4-10.7) higher in patients who developed COVID-19 3-27 days after IPD compared with patients with IPD only. Conclusions. Large declines in IPD were observed following COVID-19 lockdown. IPD/COVID-19 coinfections were rare but associated with high CFR, mainly in older adults. The rarity, age and serotype distribution of IPD/COVID-19 coinfections do not support wider extension of pneumococcal vaccination.
引用
收藏
页码：E65 / E75
页数：11
相关论文
共 50 条
  • [31] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
    Astuti, Indwiani
    Ysrafil
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (04) : 407 - 412
  • [32] Bringing Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) to the Surface: Is There a Role for Fomites?
    Katona, Peter
    Kullar, Ravina
    Zhang, Kevin
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (05) : 910 - 916
  • [33] A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
    Higdon, Melissa M.
    Wahl, Brian
    Jones, Carli B.
    Rosen, Joseph G.
    Truelove, Shaun A.
    Baidya, Anurima
    Nande, Anjalika A.
    ShamaeiZadeh, Parisa A.
    Walter, Karoline K.
    Feikin, Daniel R.
    Patel, Minal K.
    Knoll, Maria Deloria
    Hill, Alison L.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (06):
  • [34] Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota
    Vodnar, Dan-Cristian
    Mitrea, Laura
    Teleky, Bernadette-Emoke
    Szabo, Katalin
    Calinoiu, Lavinia-Florina
    Nemes, Silvia-Amalia
    Martau, Gheorghe-Adrian
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2020, 10
  • [35] Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
    Grifoni, Alba
    Weiskopf, Daniela
    Ramirez, Sydney, I
    Mateus, Jose
    Dan, Jennifer M.
    Moderbacher, Carolyn Rydyznski
    Rawlings, Stephen A.
    Sutherland, Aaron
    Premkumar, Lakshmanane
    Jadi, Ramesh S.
    Marrama, Daniel
    de Silva, Aravinda M.
    Frazier, April
    Carlin, Aaron F.
    Greenbaum, Jason A.
    Peters, Bjoern
    Krammer, Florian
    Smith, Davey M.
    Crotty, Shane
    Sette, Alessandro
    CELL, 2020, 181 (07) : 1489 - +
  • [36] Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England
    Grint, Daniel J.
    Wing, Kevin
    Houlihan, Catherine
    Gibbs, Hamish P.
    Evans, Stephen J. W.
    Williamson, Elizabeth
    McDonald, Helen, I
    Bhaskaran, Krishnan
    Evans, David
    Walker, Alex J.
    Hickman, George
    Nightingale, Emily
    Schultze, Anna
    Rentsch, Christopher T.
    Bates, Chris
    Cockburn, Jonathan
    Curtis, Helen J.
    Morton, Caroline E.
    Bacon, Sebastian
    Davy, Simon
    Wong, Angel Y. S.
    Mehrkar, Amir
    Tomlinson, Laurie
    Douglas, Ian J.
    Mathur, Rohini
    MacKenna, Brian
    Ingelsby, Peter
    Croker, Richard
    Parry, John
    Hester, Frank
    Harper, Sam
    DeVito, Nicholas J.
    Hulme, Will
    Tazare, John
    Smeeth, Liam
    Goldacre, Ben
    Eggo, Rosalind M.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E1120 - E1127
  • [37] Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients
    Mazuecos, Auxiliadora
    Villanego, Florentino
    Alonso, Angel
    Beneyto, Isabel
    Crespo, Marta
    Diaz-Corte, Carmen
    Franco, Antonio
    Gonzalez-Roncero, Francisco
    Guirado, Luis
    Jimenez, Carlos
    Juega, Javier
    Llorente, Santiago
    Paul, Javier
    Rodriguez-Benot, Alberto
    Ruiz, Juan Carlos
    Sanchez-Fructuoso, Ana
    Torregrosa, Vicente
    Rodrigo, Emilio
    Hernandez, Domingo
    Lopez, Veronica
    Lopez-Oliva, Maria
    Zarraga, Sofia
    NEFROLOGIA, 2023, 43 (05): : 531 - 545
  • [38] A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time
    Al-Awwal, Nasruddeen
    Dweik, Ferris
    Mahdi, Samira
    El-Dweik, Majed
    Anderson, Stephen H.
    PATHOGENS, 2022, 11 (03):
  • [39] SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes
    Pawlowski, Colin
    Silvert, Eli
    O'Horo, John C.
    Lenehan, Patrick J.
    Challener, Doug
    Gnass, Esteban
    Murugadoss, Karthik
    Ross, Jason
    Speicher, Leigh
    Geyer, Holly
    Venkatakrishnan, A. J.
    Badley, Andrew D.
    Soundararajan, Venky
    PNAS NEXUS, 2022, 1 (03):
  • [40] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Challenge Experiments in Nonhuman Primates: An Ethical Perspective
    DeGrazia, David
    Miller, Franklin G.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : 2121 - 2125
12345